p21‐activated kinase 4 inhibition protects against liver ischemia/reperfusion injury: Role of nuclear factor erythroid 2‐related factor 2 phosphorylation

Yuancheng Mao, Chang Yeob Han, Lihua Hao, Younho Lee, Jung Beom Son, Hwangeun Choi, Mi Rin Lee, Jae Do Yang, Suk Kyun Hong, Kyung‐Suk Suh, Hee Chul Yu, Nam Doo Kim, Eun Ju Bae, Byung‐Hyun Park – 1 February 2022

Mending the Model for End‐Stage Liver Disease: An in‐depth review of the past, present, and future portopulmonary hypertension Model for End‐Stage Liver Disease exception

Hilary M. DuBrock, Kathryn T. Valle, Michael J. Krowka – 1 February 2022 – Patients with portopulmonary hypertension (POPH) have an increased cardiovascular and overall mortality risk when undergoing liver transplantation (LT). However, such risk is not captured in their Model for End‐Stage Liver Disease (MELD) laboratory score. POPH MELD exception criteria were established in 2006 with the aim of prioritizing these patients for LT prior to pulmonary hypertension (PH) progression and eventual right heart failure.

Subscribe to